Table 2. Features of irAEs.
| Characteristic | No. (%) |
|---|---|
| Total irAEs | 274 |
| irAE type | |
| Endocrine | 84 (30.7) |
| Adrenal insufficiency | 12 (4.4) |
| Immune-mediated diabetes | 4 (1.5) |
| Thyroiditis | 53 (19.3) |
| Hypophysitis | 15 (5.5) |
| Gastrointestinal | 66 (24.1) |
| Gastroenterocolitis | 57 (20.8) |
| Pancreatitis | 7 (2.6) |
| Celiac | 1 (0.4) |
| Uvulitis | 1 (0.4) |
| Hepatobiliary | 40 (14.6) |
| Hepatotoxicity | 39 (14.2) |
| Cholangitis | 1 (0.4) |
| Pulmonary | 27 (9.9) |
| Pneumonitis | 27 (9.9) |
| Rheumatologic | 30 (10.9) |
| Arthritis | 23 (8.4) |
| PMR | 1 (0.4) |
| Myositis | 3 (8.4) |
| Sicca | 2 (0.7) |
| Vasculitis | 1 (0.4) |
| Ocular | 11 (4.0) |
| Uveitis | 6 (2.2) |
| Conjunctivitis | 5 (1.8) |
| Othera | 16 (5.8) |
Abbreviations: GI, gastrointestinal; IQR, interquartile range; irAE, noncutaneous immune-related adverse event; PMR, polymyalgia rheumatica.
a
Other irAEs included renal (nephritis, n = 6), neurologic (encephalitis, n = 2), peripheral neuropathy (n = 3), cardiac (myocarditis, n = 4), and systemic inflammatory response syndrome (n = 1).